Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986435
MYK-224 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| BMS-986435 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| MYK-224 | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | EXPERIMENTAL | - |
| Arm 1: MYK-224 | EXPERIMENTAL | - |
| Arm 2: MYK-224 + Itraconazole | EXPERIMENTAL | - |
| Arm 3: MYK-224 + Verapamil | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986435 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| MYK-224 | DRUG | Specified dose on specified days |
| Itraconazole | DRUG | Specified dose on specified days |
| Verapamil | DRUG | Specified dose on specified days |
Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any...
MYK-224 is an investigational small molecule developed by Bristol-Myers Squibb Company (NYSE: BMY). It is a Phase 1 clinical candidate that targets cardiac myosin. The specific therapeutic indication for MYK-224 has not been disclosed. It has been studied in three completed Phase 1 trials involving healthy volunteers.
MYK-224 targets cardiac myosin, a protein essential for heart muscle contraction. By interacting with cardiac myosin, the drug is designed to modulate contractility. This mechanism is being explored in early-stage clinical development. The target class is a protein, and the molecule is a small chemical entity.
MYK-224 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. Bristol-Myers Squibb is the sponsor of the clinical trials evaluating MYK-224.
MYK-224 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. Three Phase 1 trials have been completed, with a total enrollment of 88 participants. The trials were randomized, double-blind, and controlled.
MYK-224 has been evaluated in three completed Phase 1 trials: NCT05686096, an ADME study in healthy volunteers; NCT05405543, a safety and drug levels study in healthy Japanese participants; and NCT05304533, a drug interaction study with itraconazole and verapamil in healthy participants. All trials were conducted in the United States.
Yes, BMS-986435 is an alternative name for MYK-224. The ADME study NCT05686096 refers to the drug as BMS-986435, while other trials use MYK-224. Both names refer to the same investigational small molecule developed by Bristol-Myers Squibb.